Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126898632 | 12689863 | 2 | F | 20160625 | 20160907 | 20160826 | 20160915 | EXP | US-ELI_LILLY_AND_COMPANY-US201608008977 | ELI LILLY AND CO | 71.00 | YR | F | Y | 50.00000 | KG | 20160915 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126898632 | 12689863 | 1 | PS | ADCIRCA | TADALAFIL | 1 | Oral | 40 MG, QD | Y | U | 21368 | 40 | MG | TABLET | QD | ||||
| 126898632 | 12689863 | 2 | SS | ADCIRCA | TADALAFIL | 1 | Oral | 20 MG, QD | Y | U | 21368 | 20 | MG | TABLET | QD | ||||
| 126898632 | 12689863 | 3 | SS | LETAIRIS | AMBRISENTAN | 1 | Oral | 5 MG, QD | 0 | 5 | MG | QD | |||||||
| 126898632 | 12689863 | 4 | SS | LETAIRIS | AMBRISENTAN | 1 | Oral | 10 MG, QD | 0 | 10 | MG | QD | |||||||
| 126898632 | 12689863 | 5 | SS | LETAIRIS | AMBRISENTAN | 1 | Oral | 5 MG, QD | 1413104A | 0 | 5 | MG | QD | ||||||
| 126898632 | 12689863 | 6 | C | SERTRALINE | SERTRALINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 7 | C | RANITIDINE. | RANITIDINE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 8 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 9 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 10 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 11 | C | RECLAST | ZOLEDRONIC ACID | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 12 | C | ESTRADIOL. | ESTRADIOL | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 13 | C | PROCARDIA | NIFEDIPINE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 14 | C | ASPIRIN /00002701/ | ASPIRIN | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 15 | C | BIOTIN | BIOTIN | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 16 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 17 | C | ASPIR LOW | ASPIRIN | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 18 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 19 | C | POTASSIUM | POTASSIUM | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 20 | C | SERTRALINE HCL | SERTRALINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 21 | C | ACYCLOVIR /00587301/ | ACYCLOVIR | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 22 | C | PROCARDIA | NIFEDIPINE | 1 | 0 | ||||||||||||
| 126898632 | 12689863 | 23 | C | NITROFURANTOIN MACROCRYSTALS | NITROFURANTOIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126898632 | 12689863 | 1 | Product used for unknown indication |
| 126898632 | 12689863 | 3 | Pulmonary hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126898632 | 12689863 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126898632 | 12689863 | Fluid retention | |
| 126898632 | 12689863 | Hypotension | |
| 126898632 | 12689863 | Oedema peripheral | |
| 126898632 | 12689863 | Pulmonary hypertension | |
| 126898632 | 12689863 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126898632 | 12689863 | 3 | 20160617 | 0 | ||
| 126898632 | 12689863 | 4 | 20160618 | 0 | ||
| 126898632 | 12689863 | 5 | 20160627 | 0 |